Who are CsA-PG Ophthalmic Gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sandimmune, CYCLOSPORINE, CsA+ATG+Herombopag, Branded Tacrolimus, Tacrolimus - Advagraf® once daily formulation, ATG+mycophénolate mofétil+tacrolimus.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/csa-pg-ophthalmic-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

CsA-PG Ophthalmic Gel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CsA-PG Ophthalmic Gel (CsA-PG Ophthalmic Gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcineurin inhibitor. Area: Ophthalmology.

phase 3 Calcineurin inhibitor Calcineurin Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

CsA-PG Ophthalmic Gel (CsA-PG Ophthalmic Gel) — Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.. CsA-PG is a cyclosporine A prodrug formulated as an ophthalmic gel that suppresses local immune responses in the eye to treat dry eye disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CsA-PG Ophthalmic Gel TARGET	CsA-PG Ophthalmic Gel	Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.	phase 3	Calcineurin inhibitor	Calcineurin
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
CYCLOSPORINE	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01
CsA+ATG+Herombopag	CsA+ATG+Herombopag	Peking Union Medical College Hospital	marketed	Immunosuppressive agent + thrombopoietin receptor agonist combination	Calcineurin (CsA); T lymphocytes (ATG); thrombopoietin receptor (eltrombopag)
Branded Tacrolimus	Branded Tacrolimus	Novartis	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)
Tacrolimus - Advagraf® once daily formulation	Tacrolimus - Advagraf® once daily formulation	University of British Columbia	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)
ATG+mycophénolate mofétil+tacrolimus	ATG+mycophénolate mofétil+tacrolimus	University Hospital, Toulouse	marketed	Immunosuppressive combination therapy	T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-03 — Sandimmune · 8298568 · Formulation · US
2029-06-02 — Sandimmune · 9132071 · Formulation · US
2030-12-13 — Sandimmune · 8614178 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · Formulation · US
2032-04-16 — Sandimmune · 8561859 · Formulation · US
2033-08-23 — Sandimmune · 8980839 · Formulation · US
2033-08-23 — Sandimmune · 10441630 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · Formulation · US
2034-02-07 — Sandimmune · 9676525 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · Formulation · US
2036-09-29 — Sandimmune · 12496326 · Method of Use · US
2037-02-28 — Sandimmune · 11951153 · Method of Use · US
2037-02-28 — Sandimmune · 10918694 · Formulation · US
2037-09-22 — Sandimmune · 10813976 · Formulation · US
2038-11-20 — Sandimmune · 11154513 · Formulation · US
2039-10-11 — Sandimmune · 11413323 · Method of Use · US
2042-04-01 — Sandimmune · 12059449 · Formulation · US

Sponsor landscape (Calcineurin inhibitor class)

Novartis · 4 drugs in this class
Astellas Pharma Inc · 4 drugs in this class
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. · 4 drugs in this class
University of Cincinnati · 3 drugs in this class
Allergan · 3 drugs in this class
Astellas Pharma China, Inc. · 3 drugs in this class
Novaliq GmbH · 3 drugs in this class
Hoffmann-La Roche · 3 drugs in this class
LEO Pharma · 3 drugs in this class
Santen SAS · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CsA-PG Ophthalmic Gel — Competitive Intelligence Brief. https://druglandscape.com/ci/csa-pg-ophthalmic-gel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab